Having trouble accessing articles? Reset your cache.

Tolenix: Additional Phase II data

Additional data from a double-blind, crossover, international Phase II trial in 138 patients showed that twice-daily Tolenix (2 mg tolterodine plus 9 mg pilocarpine)

Read the full 249 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE